By contrast, in a PDX model of DNMT3A-WT leukaemia (AML-372), although both LSD1i and the combo treatment led to a slight increase in survival and reduction in tumour burden, the combo treatment did not show any additional benefits over LSD1i alone (Extended Data Fig. 9e,f). Here, DNMT3A is linked to leukemia.